
    
      The study is a multicenter, randomized, double-blind, placebo-controlled, active comparator,
      parallel-group study of 2 dose levels of lemborexant for 30 nights in approximately 950
      participants, 55 years or older with insomnia disorder. Participants will be males 65 years
      or older or females 55 years or older. Approximately 60% of the participants will be age 65
      years or older. The study will have 2 phases: The Prerandomization Phase and the
      Randomization Phase. Including both phases, the study will last for a minimum of 65 and a
      maximum of 81 days per participant.
    
  